CLOs on the Move


 
Kiadis Pharma is a clinical stage biopharmaceutical company focused on developing innovative and potentially life-saving therapies for blood cancer patients where pharmacological standard of care is no longer an alternative. The Company`s main focus is on the development of a cellular therapeutic that will enable partially mismatched donor stem cell transplants from family members in blood cancer patients, thus making them safe and available as the last potentially life saving option. Stem cell transplantation is currently the only potentially curative treatment available for late stage blood cancer patients; however, a standard of care matching donor is only available for half of ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.kiadis.com
  • 2525 Av Marie-curie
    Saint-Laurent, QC CAN H4S 2E1
  • Phone: 514.336.4886

Executives

Name Title Contact Details

Similar Companies

The Headline Salon- Hair Salons

The Headline Salon- Hair Salons is a Woodland Hills, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Percivia

Percivia is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Applied Proteomics

Applied Proteomics Inc. is advancing the application of proteomics to the development of diagnostics, companion diagnostics, and personalized medicine applications to power better medical decisions and care. API has developed a proteomics platform solution to make protein-based biomarker discovery possible as a replicable, industrial application ready to be applied to health diagnostic problems.

Oxford Immunotec

Oxford Immunotec is a global, commercial-stage diagnostics company committed to improving patient care by providing advanced, innovative tests in the field of immunology. Our proprietary   T-SPOT technology platform allows us to measure the responses of specific immune cells, known as T cells, to inform the diagnosis, prognosis and monitoring of patients with immunologically controlled diseases.   The initial product we have developed using our T-SPOT technology platform is our T-SPOT.TB test, which is used to test for latent Tuberculosis (TB) infection, or LTBI. Our T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where we have received pre-market approval (PMA) from the Food and Drug Administration (FDA), in Europe, where we have obtained a CE mark, as well as Japan and China. Our T-SPOT.TB test has been included in clinical guidelines (that is, guidelines issued by governmental agencies and professional societies covering recommended or suggested uses of available diagnostics) for TB screening in 17 countries, including the United States, several European countries and Japan.   We are a publicly traded company listed in the United States on the NASDAQ stock exchange (NASDAQ:OXFD).

Human BioSciences

Human BioSciences is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.